Page last updated: 2024-08-23

cicletanine and Left Ventricular Hypertrophy

cicletanine has been researched along with Left Ventricular Hypertrophy in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Agalakova, NI; Bagrov, AY; Droy-Lefaix, MT; Fedorova, OV; Lakatta, EG; Talan, MI	1

Other Studies

1 other study(ies) available for cicletanine and Left Ventricular Hypertrophy

Article	Year
Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension. Hypertension (Dallas, Tex. : 1979), 2003, Volume: 41, Issue:3 Topics: Animals; Antihypertensive Agents; Binding Sites; Blood Pressure; Bufanolides; Enzyme Inhibitors; Heart Ventricles; Hypertension; Hypertrophy, Left Ventricular; Kidney; Protein Kinase C; Protein Kinase C beta; Pyridines; Rats; Rats, Inbred Dahl; Sarcolemma; Sodium-Potassium-Exchanging ATPase	2003

Article

Year

Myocardial PKC beta2 and the sensitivity of Na/K-ATPase to marinobufagenin are reduced by cicletanine in Dahl hypertension.

Hypertension (Dallas, Tex. : 1979), 2003, Volume: 41, Issue:3

Topics: Animals; Antihypertensive Agents; Binding Sites; Blood Pressure; Bufanolides; Enzyme Inhibitors; Heart Ventricles; Hypertension; Hypertrophy, Left Ventricular; Kidney; Protein Kinase C; Protein Kinase C beta; Pyridines; Rats; Rats, Inbred Dahl; Sarcolemma; Sodium-Potassium-Exchanging ATPase

2003